Function of Cell-cycle Regulators in Predicting Silent Pituitary Adenoma Progression Following Surgical Resection

Overview

Journal Oncol Lett

Specialty Oncology

Date 2018 Jan 19

PMID 29344143

Citations 3

Authors

Sung Hyun Park

Ji Hwan Jang

Young Min Lee

Joon Soo Kim

Kyu Hong Kim

Young Zoon Kim

Affiliations

Soon will be listed here.

Abstract

The present study investigated the use of cell-cycle regulators for predicting the progression of silent pituitary adenoma (SPA) following surgical resection, via immunohistochemical analysis of tumor samples obtained by surgical resection. The medical records of patients diagnosed with SPA between January 2000 and December 2013 in the Samsung Changwon Hospital, Sungkyunkwan University School of Medicine (Changwon, South Korea) were reviewed. Immunohistochemical staining was performed on sections of the archived, paraffin-embedded tissues obtained by surgery, with all tissues stained for cell-cycle regulatory proteins p16, p15, p21, cyclin-dependent kinase (CDK)4, CDK6, retinoblastoma protein (pRb) and cyclin D1, as well as E3 ubiquitin-protein ligase mib1 (MIB-1) antigen and p53. The primary end-point was to investigate the expression of cell-cycle regulatory proteins in SPA. The secondary end-point was to estimate the progression-free survival of patients with SPA following surgical resection and to identify its association with the expression of cell-cycle regulatory proteins. Of the 127 SPA samples, 44 (34.6%) were from patients with progression during a mean follow-up period of 62.4 months (range, 24.2-118.9 months). Immunohistochemical overexpression was identified in 61 samples (48.0%) for p16, 38 samples (29.9%) for p15, 19 samples (15.0%) for p21, 49 samples (38.6%) for CDK4, 17 samples (13.4%) for CDK6, 57 samples (44.9%) for pRb and in 65 samples (51.2%) for cyclin D1. Multivariate analysis revealed that null cell adenoma [95% confidence interval (CI), 0.276-0.808], somatotroph SPAs (95% CI, 1.296-3.121), corticotroph SPAs (95% CI, 1.811-4.078), pluripotent SPAs (95% CI, 2.264-5.194), decreased expression of p16 (95% CI, 2.724-5.588), overexpression of pRb (95% CI, 2.557-5.333), cyclin D1 (95% CI, 1.894-4.122) and MIB-1 (95% CI, 1.561-4.133), increased mitotic index (95% CI, 1.228-4.079), increased p53 expression (95% CI, 1.307-4.065) and invasion into the cavernous sinus (95% CI, 3.842-7.502) predicted SPA progression following resection. The results of the present study suggested that specific cell-cycle regulators, including p16, cyclin D1 and pRb, were associated with SPA progression.

Citing Articles

Clinical Biology of the Pituitary Adenoma.

Melmed S, Kaiser U, Lopes M, Bertherat J, Syro L, Raverot G Endocr Rev. 2022; 43(6):1003-1037.

PMID: 35395078 PMC: 9695123. DOI: 10.1210/endrev/bnac010.

The kinome, cyclins and cyclin-dependent kinases of pituitary adenomas, a look into the gene expression profile among tumors from different lineages.

Taniguchi-Ponciano K, Portocarrero-Ortiz L, Guinto G, Moreno-Jimenez S, Gomez-Apo E, Chavez-Macias L BMC Med Genomics. 2022; 15(1):52.

PMID: 35260162 PMC: 8905767. DOI: 10.1186/s12920-022-01206-y.

An Update on Silent Corticotroph Adenomas: Diagnosis, Mechanisms, Clinical Features, and Management.

Jiang S, Chen X, Wu Y, Wang R, Bao X Cancers (Basel). 2021; 13(23).

PMID: 34885244 PMC: 8656508. DOI: 10.3390/cancers13236134.

References

Raappana A, Koivukangas J, Ebeling T, Pirila T . Incidence of pituitary adenomas in Northern Finland in 1992-2007. J Clin Endocrinol Metab. 2010; 95(9):4268-75. DOI: 10.1210/jc.2010-0537. View

Fernandez A, Karavitaki N, Wass J . Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf). 2009; 72(3):377-82. DOI: 10.1111/j.1365-2265.2009.03667.x. View

Chen Y, Wang C, Su Z, Chen Y, Cai L, Zhuge Q . Natural history of postoperative nonfunctioning pituitary adenomas: a systematic review and meta-analysis. Neuroendocrinology. 2012; 96(4):333-42. DOI: 10.1159/000339823. View

Mayson S, Snyder P . Silent pituitary adenomas. Endocrinol Metab Clin North Am. 2015; 44(1):79-87. DOI: 10.1016/j.ecl.2014.11.001. View

Losa M, Franzin A, Mangili F, Terreni M, Barzaghi R, Veglia F . Proliferation index of nonfunctioning pituitary adenomas: correlations with clinical characteristics and long-term follow-up results. Neurosurgery. 2000; 47(6):1313-8; discussion 1318-9. View

Knosp E, Kitz K, Perneczky A . Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67. Neurosurgery. 1989; 25(6):927-30. View

Randall R, Scheithauer W, Laws Jr E . Hormone-containing, non-secreting pituitary tumors: clinically silent monohormonal pituitary adenomas. Trans Am Clin Climatol Assoc. 1984; 96:98-103. PMC: 2279639. View

Syro L, Rotondo F, Ramirez A, Ieva A, Sav M, Restrepo L . Progress in the Diagnosis and Classification of Pituitary Adenomas. Front Endocrinol (Lausanne). 2015; 6:97. PMC: 4464221. DOI: 10.3389/fendo.2015.00097. View

Mayson S, Snyder P . Silent (clinically nonfunctioning) pituitary adenomas. J Neurooncol. 2014; 117(3):429-36. DOI: 10.1007/s11060-014-1425-2. View

10.

LANDOLT A, Shibata T, Kleihues P . Growth rate of human pituitary adenomas. J Neurosurg. 1987; 67(6):803-6. DOI: 10.3171/jns.1987.67.6.0803. View

11.

Horvath E, Kovacs K, Killinger D, Smyth H, Platts M, Singer W . Silent corticotropic adenomas of the human pituitary gland: a histologic, immunocytologic, and ultrastructural study. Am J Pathol. 1980; 98(3):617-38. PMC: 1903510. View

12.

Yonezawa K, Tamaki N, Kokunai T . Clinical features and growth fractions of pituitary adenomas. Surg Neurol. 1997; 48(5):494-500. DOI: 10.1016/s0090-3019(97)00102-x. View

13.

Horvath E, Kovacs K, Smyth H, Killinger D, Scheithauer B, Randall R . A novel type of pituitary adenoma: morphological features and clinical correlations. J Clin Endocrinol Metab. 1988; 66(6):1111-8. DOI: 10.1210/jcem-66-6-1111. View

14.

Malumbres M, Barbacid M . To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer. 2002; 1(3):222-31. DOI: 10.1038/35106065. View

15.

Srivastava V, Patel B, Kumar M, Shukla M, Pandey M . Cyclin D1, retinoblastoma and p16 protein expression in carcinoma of the gallbladder. Asian Pac J Cancer Prev. 2013; 14(5):2711-5. DOI: 10.7314/apjcp.2013.14.5.2711. View

16.

Eng J . Receiver operating characteristic analysis: a primer. Acad Radiol. 2005; 12(7):909-16. DOI: 10.1016/j.acra.2005.04.005. View

17.

Guo L, Gao P, Wu Y, Jian W, Hao C, Li H . Alteration of cyclin D1 in Chinese patients with breast carcinoma and its correlation with Ki-67, pRb, and p53. Arch Med Res. 2007; 38(8):846-52. DOI: 10.1016/j.arcmed.2007.06.004. View

18.

Gayed B, Youssef R, Bagrodia A, Kapur P, Darwish O, Krabbe L . Prognostic role of cell cycle and proliferative biomarkers in patients with clear cell renal cell carcinoma. J Urol. 2013; 190(5):1662-7. DOI: 10.1016/j.juro.2013.06.037. View

19.

Scheithauer B, Kovacs K, Laws Jr E, Randall R . Pathology of invasive pituitary tumors with special reference to functional classification. J Neurosurg. 1986; 65(6):733-44. DOI: 10.3171/jns.1986.65.6.0733. View

20.

Kirsch M, Morz M, Pinzer T, Schackert H, Schackert G . Frequent loss of the CDKN2C (p18INK4c) gene product in pituitary adenomas. Genes Chromosomes Cancer. 2008; 48(2):143-54. DOI: 10.1002/gcc.20621. View